InMed Pharmaceuticals Total Current Liabilities

InMed Pharmaceuticals (INM) currently reports a total current liabilities of $2.2B as of March 2026. That compares with $1.8B in the prior-year period — up 20.2% year over year. Use the charts on this page to explore InMed Pharmaceuticals's total current liabilities history and peer comparisons.

InMed Pharmaceuticals's total current liabilities increased from $1.8B to $2.2B — a 20.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

InMed Pharmaceuticals reported $2.2B in total current liabilities as of March 2026. That compares with $1.8B in the prior-year period — up 20.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $2.2B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for InMed Pharmaceuticals, and consider following INM for alerts when major investors trade the stock.

InMed Pharmaceuticals is classified in the Healthcare sector. On total current liabilities, it currently shows $2.2B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INM with unrelated industries.